Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients.

Pharmacogenomics - 1 Jul 2014

Gravia Aikaterini, Chondrou Vasiliki, Sgourou Argyro, Papantoni Ioanna, Borg Joseph, Katsila Theodora, Papachatzopoulou Adamantia, Patrinos George P

Abstract excerpt

Individual genetic composition is an important cause of variations in the response and tolerance to drug treatment. Pharmacogenomics is a modern discipline aiming to delineate individual genomic profiles and drug response. To date, there are several medical disciplines where pharmacogenomics is readily applicable, while in others its usefulness is yet to be demonstrated. Recent experimental evidence suggest that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia, Sickle Cell
Share to beta-Thalassemia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fetal Hemoglobin

Share to Hydroxyurea

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Share to Precision Medicine

Source

Identifiers

PMID: 25155936
DOI: 10.2217/pgs.14.101

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients.PMID 25155936Read ↗

Pharmacogenomics and therapeutics of hemoglobinopathies.Semantic proximity Read ↗

Genetic association studies in β-hemoglobinopathiesSemantic proximity Read ↗

Exploring Pharmacogenetic Factors Influencing Hydroxyurea Response in Tanzanian Sickle Cell Disease Patients: A Genomic Medicine ApproachSemantic proximity Read ↗

Genome Editing for β-Hemoglobinopathies: Advances and ChallengesSemantic proximity Read ↗

Genetic Modifiers of Hemoglobin Expression from a Clinical Perspective in Hemoglobinopathy Patients with Beta Thalassemia and Sickle Cell DiseaseSemantic proximity Read ↗

Recent Approaches for Manipulating Globin Gene Expression in Treating HemoglobinopathiesSemantic proximity Read ↗

Dissecting the role of genetic modifiers of hemoglobinopathies: A futuristic approach towards precision medicineSemantic proximity Read ↗

The search for genetic modifiers of disease severity in the β-hemoglobinopathies.Semantic proximity Read ↗

A Small Key for a Heavy Door: Genetic Therapies for the Treatment of HemoglobinopathiesSemantic proximity Read ↗

Significance of genetic modifiers of hemoglobinopathies leading towards precision medicine.Semantic proximity Read ↗

Pharmacogenomics of Drugs Used in β-Thalassemia and Sickle-Cell Disease: From Basic Research to Clinical ApplicationsSemantic proximity Read ↗

Fetal hemoglobin regulation in β-thalassemia: heterogeneity, modifiers and therapeutic approachesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.